Search

Search Constraints

You searched for: Author/Creator Short, Nicholas

Search Results

1. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia. Issue 21 (16th July 2019)

2. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Issue 3 (23rd February 2022)

3. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Issue 8 (28th May 2021)

4. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Issue 12 (21st October 2019)

5. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Issue 7 (16th April 2022)

6. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study. Issue 10 (October 2022)

8. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Issue 8 (August 2021)